Stay up to date

News

back to overview

New data from Proclarix together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis to be showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 11, 2020

Proteomedix appoints Helge Lubenow as new CEO

January 10, 2020

Proteomedix today announced the appointment of Prof. em. Dr. med. Thomas Cerny as new member of the Board of Directors.

April 10, 2019

New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis

November 9, 2018

ProteoMediX Raises CHF 5.2 million in Financing Round

August 27, 2018

Novel Biomarker Test Avoids Biopsies by Accurately Predicting High-Grade Prostate Cancer

April 13, 2018

New publication describes the development and clinical testing of ProteoMediX’ immunoassays for prostate cancer diagnosis

August 3, 2017

Dr. Helge Lubenow elected as a new member to the Board of Directors

June 21, 2017